UK startup tackles hot neoantigen field in cancer drugs
Cancer Research UK and the National Institute for Health Research have come together to back a $17.5 million round for a new upstart entering the increasingly hot neoantigen field.
The new biotech is called Achilles Therapeutics, and it’s working on developing cancer drugs based on the insights of several experts from top academic groups in the country. Their focus is on truncal tumor neoantigens, with a spotlight on lung cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.